…against interleukin 1β, provided proof of concept but was not developed for routine coronary prevention because of fatal infections and high cost. Low dose…

…level C. The European regulatory threshold described in the source material differs from the trial based threshold: ivabradine was approved for patients with HFrEF, LVEF…

…This patient was 31 years old when she died from sudden cardiac death. References An in depth discussion regarding J wave syndromes is provided by…

…to misclassification of CKD stages. Population Specificity: The equation was derived from a study population primarily consisting of individuals with CKD, limiting its accuracy when…

…figures illustrate the variation produced by differences in patient selection, procedural definitions, and institutional practice. Complications are more frequent during PCI than during purely diagnostic…

…contemporary data support the use of DES in most PCI procedures, including many patients with high bleeding risk, because newer DES provide greater efficacy with…

…since many patients reported a family history of the same symptoms and events. Perhaps the most distinguishing feature was the characteristic ST segment elevations in…

…revascularization was performed; the type of revascularization; stent related risk; whether long term oral anticoagulation is required; tolerance of treatment during the initial months. Patients…

…activation pathway; P2Y12 inhibition therefore provides complementary platelet inhibition. The clinical rationale for DAPT is particularly strong after ACS and coronary stent implantation. ACS is…

…the 20th century, widespread acceptance was delayed, partly due to autopsy studies demonstrating an absence of coronary thrombi in a significant proportion of deceased patients…